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Abstract
Background: The format or frame in which the results of randomized trials are presented has
been shown to influence health professional's self-reported practice. We sought to investigate the
effect of framing cardiovascular risk as two different formats in a randomized trial.
Methods: We recruited 457 patients aged between 60 and 79 years with high blood pressure from
20 family practices in Avon, UK. Patients were randomized to cardiovascular risk presented either
as 1) an absolute risk level (AR) or as 2) the number needed to treat to prevent an adverse event
(NNT). The main outcome measures were: 1) percentage of patients in each group with a five-year
cardiovascular risk ≥  10%, 2) systolic and diastolic blood pressure, 3) intensity of prescribing of
cardiovascular medication.
Results:  Presenting cardiovascular risk as either an AR or NNT had no impact reducing
cardiovascular risk at 12 month follow up, adjusted odds ratio 1.53 (95%CI 0.76 to 3.08). There
was no difference between the two groups in systolic (adjusted difference 0.97 mmHg, 95%CI -2.34
mmHg to 4.29 mmHg) or diastolic (adjusted difference 0.70 mmHg, 95%CI -1.05 mmHg to 2.45
mmHg) blood pressure. Intensity of prescribing of blood pressure lowering drugs was not
significantly different between the two groups at six months follow up.
Conclusions: Presenting cardiovascular risk in clinical practice guidelines as either an AR or NNT
had a similar influence on patient outcome and prescribing intensity. There is no difference in
patient outcomes when these alternative formats of risk are used in clinical practice guidelines.
Background
The results of randomized controlled trials (RCTs) and
clinical practice guidelines are based on data that esti-
mate, in numeric terms, the benefits and risks of treat-
ment [1]. Data can be presented in a number of different
formats: as an absolute risk level (AR), an absolute risk
reduction (ARR), a relative risk reduction (RRR) or as
the number of patients who need to be treated in order
that an adverse event is prevented (NNT) [2–4]. (see Fig-
ure 1 for an example of how different formats of risk can
be calculated)
Studies of self reported practice demonstrate that inter-
pretation by physicians of numeric data may vary de-
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pending on the format or the "frame" in which they are
presented [1]. In clinical scenarios, results expressed as a
relative risk reduction are viewed more positively by
health professionals than when they are expressed as ab-
solute differences [1]. However, some studies suggest
framing effects may occur between different absolute
risk formats; for example primary care physicians are
more likely to prescribe anti-hypertensive drugs when
results are presented as an ARR than when the same re-
sults are presented as an NNT [5]. Such observations are
of importance when attempting to ensure that clinical
practice is based on highest quality evidence. If physi-
cians are influenced by the "framing" of data presented
in clinical practice guidelines or in pharmaceutical pro-
motional material [6], their clinical practice may be sys-
tematically biased [1].
Case scenarios of intended clinical practice may not pre-
dict actual clinical behaviour [7]. As the existing litera-
ture is confined to examination of physicians' opinion or
their intended clinical practice, the effect of "framing" on
actual clinical practice has not yet been estimated [1]. We
aimed to investigate in a randomized controlled trial the
effect of "framing" cardiovascular risk when two differ-
ent but equivalent formats were used: as an absolute risk
level (AR) versus number needed to treat (NNT).
Methods
All patients aged 60–80 years with a diagnosis of hyper-
tension and a record of having been prescribed anti-hy-
pertensive medication in the previous year were eligible.
Thirty eligible patients were randomly sampled from
each practice list using either the computer system's
built-in sampling facility (EMIS practices) or a random
sampling programme on a personal computer (AAH
Meditel practices). Patients were recruited to a study in-
vestigating the use of New Zealand practice guidelines
for the management of high blood pressure. These prac-
tice guidelines specifically quantify the absolute risk of a
cardiovascular event (newly diagnosed angina, myocar-
dial infarction, coronary heart disease, stroke or tran-
sient ischaemic attack) over a five year period and are
based on a Framingham risk equation [8]. The guide-
lines are formatted in such a way that when an individu-
al's age, sex, smoking status, presence or absence of
diabetes, total:HDL cholesterol ratio and blood pressure
level are elicited their absolute risk of a cardiovascular
event can be read directly from a coloured chart (see:
[http://cebm.jr2.ox.ac.uk/docs/prognosis.html] ). This
method of risk assessment has been proposed as a ra-
tional way on which to base treatment recommendations
for patients with high blood pressure [9].
Study design
Twenty seven Family practices were randomly allocated
to receive the practice guidelines in either computerised
format plus a coloured chart, the chart guidelines only,
or usual care (no guidelines). The results of this rand-
omized study have been published separately [10]. In a
factorial design, the twenty family practices receiving the
practice guidelines in the chart and computerised format
were further randomly allocated to have risk presented
during the consultation as AR or NNT (the seven "usual
care" practices did not receive charts, thus were unable
to participate in this part of the randomized trial). The
risk tables classify patients into one of six absolute risk
categories (<2.5%, 2.5 to 4.9, 5.0 to 9.9, 10.0 to 14.9, 15
to 19.9, >20% over five years). The equivalent NNTs for
these absolute risks were presented assuming that blood
pressure lowering led to a relative risk reduction of one
third. Patients had their blood pressure measured and
risk assessed at baseline, six and 12 months follow-up.
Local research ethics committee approval was obtained
to undertake the study.
Outcomes
The primary outcome was the proportion of patients in
each group with cardiovascular risk ≥  10% over five-
years at 12 months follow up. Secondary outcomes were
systolic and diastolic blood pressure at 12 months; and
intensity of changes in prescribing of blood pressure low-
ering medication at six months follow up. Blinding the
Figure 1
Example of how data from randomized trials can be pre-
sented as different formats of risk in the treatment of hyper-
tension. Adapted from reference [3].BMC Health Services Research 2001, 1:10 http://www.biomedcentral.com/1472-6963/1/10
health professionals to intervention group was not possi-
ble given the nature of the study. No attempt was made
to blind the data analysts (TP, AM & TF) to the study
group.
Analysis
All data analyses were carried out using Stata statistical
software. Multivariable analyses were performed exam-
ining the impact of alternative framing formats (AR or
NNT) on outcome, adjusting for intervention group from
the other factorial element of the trial (chart plus compu-
ter or chart alone), outcome variable at baseline and type
of computer system used in the family health centre (one
of two different computer systems). Since randomisation
was by practice, we also corrected for clustering effects
using procedures in Stata to derive robust estimates of
standard error. As observational studies have reported
on the intention of prescribing in physicians in the con-
text of different framing of risk [1], we measured the in-
tensity of prescribing of blood pressure lowering drugs at
baseline and six months follow up. Prescribing intensity
was categorised into three groups: 0 or 1; 2; 3 or more
different classes of blood pressure lowering drugs. Dis-
tribution of prescribing intensity was compared by
means of Χ 2 test and multinominal logistic regression
models that allowed for the distributions of prescribing
intensity at baseline.
Sample size calculation
With 93 patients in each arm, a difference of 20 percent-
age points in the proportion of patients at cardiovascular
risk of ≥  10% could be detected with 80% power and a
two sided 5% significance level [10]. This sample size was
inflated by a factor of 2.05 based on an intrapractice cor-
relation coefficient of 0.0551 to allow for randomisation
by practice [11,12]. This resulted in a sample size require-
ment of 190 patients for each arm of the randomized tri-
al.
Results
Baseline data were collected from 457 patients and 12-
month follow-up data from 401 (88%) patients (Figure
2). As would be expected in an elderly population, over
80% of patients in both comparison groups had a five
year cardiovascular risk of 10% or more. Other baseline
characteristics are presented in Table 1. Adjusting for the
clustering effect of using practice as the unit of randomi-
sation did not affect the results so the unadjusted analy-
ses are reported. Cardiovascular risk increased in both
groups during the 12 months of follow up (Table 2). After
adjustment for baseline differences, practice computer
system and method of presentation (computer or risk
chart) there were no statistically significant differences
between the AR and NNT groups in terms of primary and
secondary outcome variables at 12 months (Table 3).
Intensity of prescribing of blood pressure lowering drugs
also increased within both groups during the six months
of follow up (Table 4). However, when baseline prescrib-
ing was controlled for using multinominal regression,
there were no statistically significant differences be-
tween the AR and NNT groups in prescribing intensity
(Table 5). The CONSORT checklist is available – see
1additional file
Discussion
Using charts that estimate cardiovascular risk is being
promoted as the most rational way to manage high blood
pressure and other cardiovascular risk factors [9]. Such
an approach has been adopted in the UK and New Zea-
land [13,14]. Less explicit risk-stratification is recom-
mended in the US blood pressure guidelines [15]. It
seems likely that provision of individualised risk infor-
mation will become the starting point for evidence-based
management of hypertension and other forms of cardio-
vascular disease [16]. In the context of individualised
risk and the evidence from observational studies of
"framing" effects, it is critically important to establish
whether a particular format of presenting risk is superior
to another. This randomized trial has shown that there
appears to be little difference in presenting risk either as
an AR and NNT in consultations with patients in terms
of their subsequent cardiovascular risk, systolic or di-
astolic blood pressure levels, or prescribing intensity.
The confidence limits around these estimates do not rule
out a potentially important benefit favouring presenta-
Figure 2
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tion of risk as an AR in terms of systolic blood pressure
(the upper limit of 95% confidence limit was 4.29 mm-
Hg) but this finding would require confirmation in a
larger study.
Of the thirteen observational studies that have examined
"framing" effects only one explicitly considered its im-
pact on the treatment of high blood pressure [5]. This
study suggested that presenting risk as an ARR was likely
to be associated with more intensive drug prescribing
than when risk was presented as an NNT. Our rand-
omized trial, though not directly equivalent as risk was
presented as an AR rather than ARR, does not confirm
this finding. Rather it reinforces the finding from other
Table 1: Baseline characteristics of trial participants
Absolute Risk (n = 232) NNT(n = 225)
Mean age (SD) in years 70.4 (5.5) 70.4 (5.5)
Female 123 (53%) 130 (58%)
Five year cardiovascular risk ≥  10% 194 (83.6%) 193 (85.8%)
Mean absolute 5-yr risk in % (SD) 17.9 (8.2) 18.4 (8.6)
Mean SBP in mmHg (SD) 152 (19) 157 (19)
Mean DBP in mmHg (SD) 85 (10) 86 (9)
Mean BMI (SD) 27.4 (4.5) 27.0 (4.3)
Mean total cholesterol mmol/l (SD) 6.1 (1.0) (n = 137) 6.0 (1.0) (n = 143)
Mean HDL cholesterol mmol/l (SD) 1.3 (0.3) (n = 12) 1.2 (0.3) (n = 16)
Current smoker 34 (14.7%) 29 (12.9%)
Diabetes 26 (11.2%) 23 (10.2%)
Left Ventricular Hypertrophy 5 (2.2%) 9 (4.0%)
Atrial fibrillation 12 (5.2%) 15 (6.7%)
Angina 21 (9.1%) 29 (12.9%)
Transient Ischaemic Attack 10 (4.3%) 10 (4.4%)
Angioplasty 1 (0.4%) 4 (1.8)
Peripheral Vascular Disease 9 (3.9%) 13 (5.8%)
Coronary Artery Bypass Graft 1 (0.4%) 3 (1.3%)
Previous Myocardial Infarction 20 (8.6%) 13 (5.8%)
Previous Stroke 9 (3.9%) 6 (2.7%)
Family history of Ischaemic Heart Disease 34 (14.7%) 48 (21.3%)
Family history of stroke 29 (12.5%) 38 (16.9%)
Family history of hypercholesterolaemia 8 (3.4%) 1 (0.4%)
Table 2: Unadjusted risk of a cardiovascular event (5 year), mean systolic and diastolic blood pressure at 12-month follow up in the two 
comparison groups (AR vs NNT)
Outcome Risk presented as Absolute Risk (AR)
 (n = 205)
Risk presented as Number Needed 
to Treat (NNT) (n = 196)
Cardiovascular risk n (%) Baseline 12 months Baseline 12 months
0% to 9.9% 40 (20%) 26 (13%) 36 (18%) 29(15%)
10% to 19.9% 104 (51%) 108 (53%) 104 (53%) 109 (56%)
≥  20% 61 (30%) 71 (35%) 56 (29%) 58 (30%)
Mean cardiovascular risk (sd) 16.4 (7.4) 18.0 (7.6) 16.8 (7.4) 17.3 (7.7)
Difference (se) 1.6 (0.3) 0.6 (0.4)
Mean systolic BP mmHg (SD) 152 (19) 153(17) 157 (18) 154 (20)
Difference (se) -0.6 (1.3) -3.4 (1.5)
Mean diastolic BP mmHg (SD) 85 (10) 86 (9) 86 (9) 85 (9)
Difference (se) -0.3 (0.7) -1.1 (0.8)BMC Health Services Research 2001, 1:10 http://www.biomedcentral.com/1472-6963/1/10
studies of "framing" effects, which suggest that absolute
risk formats, either an AR, ARR or NNT have the same
impact on health professionals' prescribing intentions
[1].
The NNT has been promoted as a clinically useful meas-
ure of treatment effect [2,4]. Some commentators have
criticised the use of the NNT as an index of risk that may
be difficult for health professionals to understand and
use [17]. We found no evidence that patients' outcomes
or prescribing intensity changed when the NNT was used
in clinical practice guidelines compared with when AR
was used as the format of presentation. However, routine
use of the NNT may be problematic. Pooled NNTs de-
rived from meta-analyses can be seriously misleading if
baseline risk varies between randomized trials. [18] Fur-
thermore, the use of an "adjusted" NNT(a ratio measure-
ment of the NNT and NNH, number needed to harm) –
has been proposed as a further refinement when decid-
ing on the risks and benefits of treatment in individual
patients [16]. It is not altogether clear whether such re-
finements will serve to help or confuse patients and
health professionals, when discussing cardiovascular
risk in the context of deciding on drug treatment [17]. It
might reasonably be argued that the impact of framing is
unlikely to have a large effect on either professional be-
haviour (as measured by changes in the intensity of
blood pressure lowering drugs) or patient outcome
(measured by changes in cardiovascular risk and blood
pressure readings). This study shows that large effects on
professional behaviour and patient outcome are unlikely
to occur when risk information is presented in absolute
terms, either as an NNT or AR.
There are several shortcomings with the present study.
Cardiovascular risk in recruited patients was higher than
Table 3: Adjusted* risk of a cardiovascular event (5 year), mean systolic and diastolic blood pressure at 12-month follow up in the two 
comparison groups (AR vs NNT)
Outcome variable
Risk presented as 
Absolute Risk (AR) 
(n = 205)
Risk presented as 
Number Needed to 
Treat (NNT) 
(n = 196)
5-year cardiovascular risk 180 (87.8%) 168 (85.7%) Adjusted odds ratio = 1.53 p = 0.23
≥  10% (95%CI 0.76,3.08)
Mean absolute 5-yr risk in 18.3 (8.0) 18.1 (8.0) Adjusted difference = 0.69 p = 0.16
%(SD) (95%CI -0.27,1.66)
Mean SBP in mmHg (SD) 153 (17) 154 (20) Adjusted difference = 0.97 
(95%CI -2.34,4.29)
p = 0.56
(95%CI -2.34,4.29)
Mean DBP in mmHg (SD) 86 (9) 85 (9) Adjusted difference = 0.70 
(95%CI -1.05,2.45)
p = 0.43
(95%CI -1.05,2.45)
Outcome variables adjusted for baseline measurement of outcome variable, practice computer system and method of presentation of risk (chart or 
computer)
Table 4: Number (%) of patients prescribed different numbers of blood pressure lowering drugs at baseline and six-month follow-up in 
the two comparison groups (AR vs NNT)
Risk presented as Absolute Risk (AR)
 (n = 210)
Risk presented as Number Needed 
to Treat (NNT) (n = 205)
Number of classes of drugs prescribed Baseline 6 months Baseline 6 months
of drugs prescribed
0–1 92 (44) 72 (34) 94 (46) 77 (38)
2 67 (32) 67 (32) 66 (32) 74 (36)
3+ 51 (24) 71 (34) 45 (22) 54 (26)BMC Health Services Research 2001, 1:10 http://www.biomedcentral.com/1472-6963/1/10
anticipated, with the consequence that the study was un-
der – powered to detect a difference in the primary out-
come measure. However, all secondary outcome
measures, systolic and diastolic blood pressure and pre-
scribing intensity of blood pressure lowering drugs were
unaffected by the format of risk presentation. A sample
size of over 3000 patients would be necessary if a differ-
ence of 2 mmHg in systolic blood pressure was thought
to be clinically important enough to detect. The interven-
tion was directed at health professionals not patients. We
do not know to what extent health professionals dis-
cussed management of hypertension with their patients
and are therefore uncertain whether presenting risk in
different formats would have a similar effect on patients.
Lastly, a third arm of presenting risk as a relative risk re-
duction was not undertaken. Generation of a CDSS or
production of a risk chart based on absolute risk does not
facilitate presentation of risk in relative terms. All blood
pressure lowering drugs produce a relative risk reduc-
tion of about one third. Producing a chart stating this
single fact seemed unlikely to be of use to health profes-
sionals or patients.
At present clinical practice guidelines do not go beyond
measurements of treatment efficacy, often ignoring the
potential for harm and the impact of patients' preferenc-
es [3]. However, this situation is changing [19]. At the ba-
sic level, informed decision making should require
estimates of treatment efficacy (both in absolute and rel-
ative terms); some measure of susceptibility to the target
outcome (the absolute risk); and some measure of how
precise these estimates are (95% confidence limits
around the estimates) [3]. It is notable that no current
cardiovascular guidelines in the UK provide this level of
information in primary care. Lastly, pictorial representa-
tion of cardiovascular risk may well be subject to system-
atic bias in the same way that "framing" effects may exist.
As a large proportion of cardiovascular risk guidelines
rely on some form of pictorial representation of risk,
careful consideration and empirical testing should be
given to the most effective way data are displayed in clin-
ical practice guidelines [20].
Conclusions
This randomized trial suggests that use of either the AR
or the NNT should be a matter of choice for health pro-
fessionals using hypertension guidelines. Further stud-
ies should examine the impact of using the NNT as an
index of risk in terms of patients' preferences for treat-
ment choices, as well as the use of other data display for-
mats, aside from risk tables, in clinical practice
guidelines.
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